Objective: Despite effective antiretroviral therapy (HAART) and durable viral suppression, many HIV-infected individuals still do not achieve CD4 þ cell count (CD4 þ ) normalization. Vitamin D has immunoregulatory functions, including inducing the development of T cells and higher levels may improve CD4 þ rebound. Methods: CD4 þ rebound was modeled using a nonlinear mixed effects model. We estimated the adjusted effect (adjusted for pre-HAART antiretroviral exposure, black race, age and CD4 þ at HAART initiation) of pre-HAART and post-HAART vitamin D metabolite levels on the rate of CD4 þ increase and final CD4 þ plateau.
Methods: CD4 þ rebound was modeled using a nonlinear mixed effects model. We estimated the adjusted effect (adjusted for pre-HAART antiretroviral exposure, black race, age and CD4 þ at HAART initiation) of pre-HAART and post-HAART vitamin D metabolite levels on the rate of CD4 þ increase and final CD4 þ plateau.
Results: Among the 263 HIV-infected HAART initiators with pre-HAART vitamin D measurements, a 1-SD higher pre-HAART 25(OH) 2 D level was associated with a 9% faster rate of rise (P ¼ 0.02) but no gain in final CD4 þ plateau. In contrast, a 1-SD higher 1,25(OH) 2 D level was associated with a 43-cell lower final CD4 þ (P ¼ 0.04). Among 560 men with post-HAART measurements, findings were similar to those for pre-HAART 25(OH) 2 D with 1-SD higher level associated with faster rate of rise but no improvement in final CD4
þ .
Introduction
HIV-1 infection is characterized by a progressive deterioration in immune function. The advent of effective therapy (HAART) has allowed the vast majority of patients who achieve and maintain undetectable plasma HIV RNA levels to experience sustained improvements in immune function, leading to eventual recovery of their CD4 þ cell count (CD4 þ ) [1] [2] [3] [4] . However, substantial heterogeneity in the rate of increase and the apparent plateau of CD4 þ has been noted, and a significant proportion of individuals who start HAART fail to achieve adequate CD4 þ reconstitution [5] [6] [7] [8] , even after up to 10 years of treatment-mediated viral suppression [9] . Although persons initiating therapy with a CD4 þ less than 200 cells/ml are most at risk of a suboptimal CD4 þ recovery, an estimated 17-52% of patients initiating therapy with higher CD4 þ s also fail to achieve a CD4 þ plateau of greater than 500 cells/ml [7, 8, 10] .
Persistently low CD4 þ s despite virally suppressive HAART is associated with increased risk of both AIDS-related and non-AIDS-related events [11] [12] [13] [14] [15] [16] . Evidence suggests continuous improvements in clinical prognosis with higher CD4 þ s maintained during therapy until 1500 cells/ml, at which point overall prognosis approaches that of an HIV-uninfected individual [16] . Thus, interventions targeting modifiable factors that could improve CD4 þ reconstitution following HAART initiation may impact AIDS-related and non-AIDS-related comorbidity rates.
One potential target is vitamin D level status. Vitamin D has immunoregulatory functions, and all cells of the immune system including T lymphocytes cells have been shown to express vitamin D receptors [17] . The active form of vitamin D, 1,25(OH) 2 D, acts as a potent anti-inflammatory agent and induces development of regulatory T cells [18] . Deficiency of 1,25(OH) 2 D has been linked to multiorgan immune-mediated damage [19] . Given that immune activation [20] [21] [22] and reduced regulatory T-cell frequencies [23] both appear to predict CD4 þ loss and disease progression, vitamin D status could play a role. Consistent with this hypothesis, prior studies in HIV-infected patients have shown a correlation between both pre-HAART and post-HAART 25(OH)D levels and CD4 þ T-cell recovery [24, 25] .
In this study, we measured pre-HAART and post-HAART levels of 25(OH)D and its active form, 1,25(OH) 2 D, and evaluated their associations with the rate of CD4 þ reconstitution and CD4 þ plateau among HIV-infected participants initiating HAART in the Multicenter AIDS Cohort Study (MACS).
Methods and methods
The multicenter AIDS cohort study Established in 1984, the MACS is an ongoing observational study of HIV-infected and HIV-uninfected MSM from four recruitment sites: Baltimore, MD-Washington, DC; Chicago, IL; Los Angeles, CA; and Pittsburgh, PA [26] . At semiannual visits participants undergo physical examinations and give blood and urine samples for laboratory analyses and storage. Standardized questionnaires are used to collect health, behavior and HIV treatment history. Each participant gives informed consent and each local institutional review board has approved the study.
For the current study, we included men with pre-HAART or post-HAART vitamin D metabolite measurements from the MACS vitamin D substudy [27] , who had at least one post-HAART CD4 þ measurement and evidence of viral suppression (defined as at least one HIV RNA measurement <500 copies/ml within 2 years of starting HAART) following HAART initiation. Included men were followed from HAART initiation (defined as the midpoint between last observed time not on HAART to first observed time on HAART) until viral failure (defined as HIV RNA measurement >500 copies/ml 2 years or more after starting HAART) or last CD4 were measured using immuno-affinity purification and liquid chromatography-tandem mass spectrometry [28] .
Covariate measurements
Race, smoking, alcohol use and IDU were ascertained from self-report. BMI was recorded from physical examination. Plasma HIV-1 RNA levels were measured using Roche assays (Hoffman-LaRoche, Nutley, New Jersey, USA). CD4 þ lymphocyte counts were measured using standardized flow cytometry. HAART was defined as three or more antiretroviral drugs consisting of one or more protease inhibitors or one nonnucleoside reverse transcriptase inhibitor or nucleoside reverse transcriptase inhibitor: abacavir or tenofovir disoproxil fumarate, or an integrase strand transfer inhibitor or an entry inhibitor [29] based on reported therapy use. We used a binary variable to account for differences in treatment in different therapy eras (pre-2000, 2000 and after). Exposure to antiretrovirals prior to HAART initiation was also captured. Prevalent hepatitis C virus (HCV) was defined as a reactive HCV antibody or detectable HCV RNA level. Plasma HIV RNA levels were measured using the Roche Amplicor assay (Hoffman-LaRoche, Nutley, New Jersey, USA) sensitive to 50 copies/ml. CD4 þ was measured by three-color flow cytometry (34) . Evidence of viral suppression was defined as at least one HIV RNA measurement less than 500 copies/ml within 2 years of starting HAART, whereas failure following viral suppression was defined as a HIV RNA measurement more than 500 copies/ml 2 years or more after starting HAART among men with evidence of post-HAART suppression.
Baseline covariate values of age and CD4 þ were taken from the closest visit prior to the estimated date of HAART initiation. If CD4
þ was missing at the closest visit, the pre-HAART nadir CD4 þ was used.
Statistical analysis
Adjustment of vitamin D levels for seasonal variation Serum 25(OH)D levels vary by season [30] . To adjust for seasonal variation, we used a linear regression model with 25(OH)D as the dependent variable and the season of blood collection as a categorical independent variable (January-March, April-June, July-September, October-December). We estimated the seasonally adjusted 25(OH)D value by adjusting out the seasonal variation (adding the residuals of the model to the model intercept). These estimates of the seasonally adjusted 25(OH)D value were used in all subsequent analyses.
Modeling of CD4
R rebound following HAART initiation CD4 þ rebound was modeled using a nonlinear mixed effects model which described the process of CD4 þ increase as an exponential function of time since HAART initiation [31, 32] . The model had three parameters which included the starting CD4 þ (starting count; S) at HAART initiation, the plateau or final level of CD4 þ (final count; F) following recovery and the rate at which CD4 þ increased (rate of increase; R). To satisfy distributional assumptions and improve convergence, CD4 þ was transformed by taking the natural log and multiplying by 5. Thus, the model had the following form:
where CD4
þ ij and t ij refer to the CD4 þ and respective time point j of each measurement for individual i. Random effects were added to each parameter to allow for individual variability in the starting count, final count and rate of increase. Each parameter (i.e. S, F or R) could be described as a function of covariate values. To evaluate model fit and describe CD4 þ rebound in the MACS sample, the model was adjusted for observed CD4 þ at HAART initiation. Men were censored from the analysis at the time they experienced viral failure.
The relationship between vitamin D metabolite levels and CD4 R rebound To evaluate the effect of vitamin D metabolite levels, each parameter (i.e. S, F, or R) was described as a function of vitamin D levels and/or potential confounding covariates. Pre-HAART vitamin 25(OH)D and 1,25(OH) 2 D levels were included in the expressions for starting count, S, as well as equations for final count, F, and rate of increase, R. Post-HAART vitamin 25(OH)D and 1,25(OH) 2 D levels were included only in the expressions for final count, F and rate of increase, R, as post-HAART vitamin D levels were not expected to affect the starting CD4 þ . Examined covariates for inclusion as possible confounders were CD4 þ at HAART initiation, age at HAART initiation, BMI at HAART initiation, viral load at HAART initiation, black race, IDU, smoking, alcohol use, HCV infection, antiretroviral use prior to HAART initiation and pre-2000 HAARTera. The final adjusted model was the most parsimonious model with the lowest Akaike information criterion and with all included covariates (except the exposure of interest: 25(OH)D and 1,25(OH) 2 D levels) having a P value less than 0.05. Thus, covariates could be included in any parameter function or none depending upon the above criteria.
The analysis was conducted using SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Sample selection A total of 645 HIV-infected men had post-HAART 25(OH)D and 1,25(OH) 2 D measurements from the MACS vitamin D substudy. Of these, 560 men had at least one CD4 þ measurement to contribute to the analysis and evidence of HIV viral suppression following HAART initiation. Among the 560, 263 men also had pre-HAART initiation vitamin D measurements. At HAART initiation, the median age was 43 years and 25% were African-American (Table 1) . On average, men were observed for 8.1 years following HAART initiation. Comparing men included with all HAART initiators, men included were more likely to have initiated therapy before 2005 and were older at HAART initiation (P < 0.01). (Table 1) . Overall, only 2% of men reported any current vitamin supplementation use at the first visit following HAART initiation and supplementation use was not differential by post-HAART 25(OH)D level.
Description of CD4
R recovery by starting CD4 (Table 2) . As a measure of the rate of CD4 þ gain, the median predicted time to 75% of the final CD4 þ was 1.9, 1.5 and 0.4 years, respectively. The predicted percentage of each group achieving a CD4 þ of at least 500 cells/ml following HAART initiation was 53, 79 and 92%, respectively. Having a higher baseline CD4 þ was correlated (r ¼ À0.2) with a higher final CD4 þ and a higher baseline CD4
þ was correlated with a slower rate of rise (r ¼ À0.2), as has been previously reported. The strongest correlation was between a faster rate of rise and a lower final CD4 þ (r ¼ À0.4).
Relationship between vitamin D status and CD4
R recovery The final model was adjusted for ART exposure before HAART, baseline age, black race and CD4 þ at HAART initiation.
Among the 263 men with pre-HAART vitamin D measurements, the associations of pre-HAART 25(OH)D and 1,25(OH) 2 D levels with final CD4 þ and rate of CD4 þ increase were examined (Table 3) . We found that for the average participant, an additional 10 ng/ml 25(OH)D (equivalent to 1 SD of change) was associated with a 9% faster median time to 75% of the final value (P ¼ 0.02). In contrast, a 16 pg/ml higher pre-HAART 1,25(OH) 2 D level (equivalent to 1 SD of change) was associated with a 29-cell lower starting CD4 þ (P ¼ 0.04) and a 43-cell lower final CD4 þ (P ¼ 0.04), holding pre-HAART 25(OH)D set at the mean pre-HAART cohort level. Among the 560 men with post-HAART vitamin D measurements, we found that for the average participant, an additional 10 ng/ml post-HAART 25(OH)D was associated with a 10% faster median time to 75% of the final value (P ¼ 0.01) ( Table 3 ). Figure 1 shows the average projected CD4 þ rebound by post-HAART 25(OH)D tertile and the associated variability in individual trajectories. When post-HAART 1,25(OH) 2 D levels were added to the models, a 16 pg/ml higher post-HAART 1,25(OH) 2 D level was associated with a 6% faster median time to 75% of the final value (P ¼ 0.003), holding post-HAART 25(OH)D set at the mean cohort level.
Predictors of CD4
R recovery We compared men with predicted final CD4 þ of at least 500 cells/ml to men with final CD4 þ less than 500 cells/ ml, stratified by observed CD4 þ at HAART initiation to identify characteristics associated with achieving adequate immune reconstitution, independent of the CD4 þ category at HAART initiation. Among men with CD4 þ less than 200 cells/ml at HAART, nonblack men were more likely to achieve 500 cells/ml (59 versus 34%). Men with lower pre-HAART 1,25(OH) 2 D were also more likely to achieve 500 cells/ml (mean pre-HAART 1,25(OH) 2 D: 41.7 versus 49.6 pg/ml). Among men with CD4 þ between 200 and 350 cells/ml, those with no prior antiretroviral exposure before HAART were more likely to achieve 500 cells/ml (86 versus 70%). Among men with CD4 þ greater than 350 cells/ml, the vast majority achieved 500 cells/ml. Neither levels of pre-HAART nor post-HAART 25(OH)D were significant predictors of CD4 þ recovery.
Discussion
There is substantial heterogeneity in the CD4 þ value achieved following HAART initiation, which is only partially explained by CD4 þ at HAART initiation. The consequence of persistent low CD4 þ during treatment is the increased risk of both AIDS-related and non-AIDSrelated events [1116] . Some evidence suggests continuous
Vitamin D and CD4
R recovery in HIVR men Abraham et al. 1073 Table 2 . Description of estimated CD4 R T-cell count rebound following HAART initiation by category of observed CD4 R T-cell count at HAART initiation.
Observed CD4
þ at HAART initiation Estimated parameters Overall improvements in a patient's overall prognosis with higher maintained CD4 þ during therapy until 1500 cells/ml, at which point overall prognoses approach that of HIVuninfected individuals [16] . Finding interventions that may bolster immune rebound following HAART initiation could, therefore, have notable effects on long-term morbidity. Although vitamin D status is a promising target for intervention given the role of 1,25(OH) 2 D in immune system regulation, we found little evidence to suggest that higher levels of either inactive or active vitamin D metabolites were associated with improved CD4 þ rebound.
Pre-HAART levels of 25(OH)D and 1,25(OH) 2 D were examined in relation to CD4 þ rebound in a subset of the cohort with pre-HAART measurements. We found that higher pre-HAART 25(OH)D levels were associated with modestly faster rises in CD4 þ but unchanged or perhaps higher final CD4 þ plateaus. However, contrary to the expectation that higher levels of vitamin D metabolites would be beneficial, we found higher pre-HAART 1,25(OH) 2 D levels were associated with a much lower final CD4 þ plateau -43 cells lower per SD increase in pre-HAART active vitamin D. It has been suggested that 1,25(OH) 2 D levels may serve as a clinical marker in autoimmune and chronic disease [33] , and chronic HIVinfection may represent a similar context of long-term immune activation. Dysregulation of vitamin D metabolism either through downregulation of vitamin D receptor activity or through increased 1a-hydroxylase activity could allow 1,25(OH) 2 D levels to rise, with the former a common mechanism used by invading pathogens to evade the host immune response [34] . There is little prior research evaluating the active form of vitamin D and its association with CD4 þ rebound. A prior study of 54 HIV-infected patients and 20 controls found lower levels of 1,25(OH) 2 D to be associated with HIV-infection but not with CD4 þ cell count, but 27 patients met criteria for AIDS, which may represent a different population and immune context [35] . Prior reports from the MACS vitamin D substudy found no difference in median 1,25(OH) 2 D level by HIV serostatus (median 45.0 pg/ml in HIV-infected and 45.1 pg/ml in HIV-uninfected [27] ). It must be emphasized that the reliability of 1,25(OH) 2 þ rate of rise and final resulting value was consistent across the data, suggesting that those with faster immune system gains also see a premature end to recovery, plateauing at a lower final CD4 þ . However, continued gains after 4 or 5 years among even those with low baseline CD4 þ has been reported [3, 4] . Indeed we saw that estimated median time to within 50 cells of the CD4 þ asymptote was estimated to be around 4 years after HAART initiation and was the same regardless of the initial pre-HAART CD4
þ . This suggests that gains for half of the population may continue beyond 4 years following HAART initiation, even in persons with the most compromised immune systems. Thus, the consistency of the estimate of final time to CD4 þ asymptote supports prior observations that the immune system's capacity for CD4 þ T lymphocyte restoration is not necessarily limited by low pretherapy CD4 þ cell counts. The recovery of the CD4 þ T-cell count has been reported to be hindered by residual viral replication, impaired thymic function, advanced age, enhanced T-cell activation and apoptosis, and, possibly, viral coinfection [7, [10] [11] [12] [13] . In our sample of men who were suppressed following HAART initiation, we could not examine the impact of residual viral replication. However, neither age nor HCV coinfection were significant predictors of attaining 500 cells/ml. Of the factors we examined, we found that a lack of prior antiretroviral exposure, lower pre-HAART 1,25(OH) 2 D and nonblack race were the only significant predictors of attaining a plateau of at least 500 cells/ml.
There were limitations to our study worth noting. Measured 25(OH)D and 1,25(OH) 2 D levels pre-HAART and post-HAART initiation were used to represent long-term vitamin D status that could affect CD4 þ rebound possibly over many years. The half-life of 25(OH)D and 1,25(OH) 2 D levels is on the order of days for the former and hours for the latter, which could introduce substantial measurement error into the analysis if there is large variability over time. Correlations between pre-HAART and post-HAART measurements suggests moderate stability, particularly in 25(OH)D levels. Second, censoring of individuals when viral load rose above 500 cells/ml may have introduced informative censoring such that those with poorer response were selectively removed from the analysis. Therefore, estimates of final CD4 þ and the percentage obtaining a final count above 500 cells/ml may be overly optimistic.
In conclusion we found no evidence to suggest higher vitamin D metabolite levels are associated with better CD4 þ outcomes in a sample of HIV-infected men with evidence of viral suppression following HAART initiation. Although vitamin D metabolite supplementation has been posited to be a potential intervention that might improve CD4 þ response to therapy, our data do not support this assertion. Further studies could examine whether 1,25(OH) 2 D levels prior to HAART initiation have value as a clinical marker of immune response dysregulation.
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